Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -93,063 | -62,656 | -25,606 | -25,489 | -51,777 |
| Depreciation Amortization | 2 | 2 | 1 | N/A | 19 |
| Accounts receivable | 831 | 831 | 831 | 831 | -831 |
| Other Working Capital | -4,898 | -3,960 | -2,560 | 852 | 3,453 |
| Other Operating Activity | 59,425 | 39,360 | 12,925 | 20,791 | 46,871 |
| Operating Cash Flow | $-37,703 | $-26,423 | $-14,409 | $-3,015 | $-2,265 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -7 | -7 | -3 | N/A | -2 |
| Investing Cash Flow | $-7 | $-7 | $-3 | $N/A | $-2 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 620 |
| Debt Repayment | -176 | -177 | N/A | N/A | N/A |
| Common Stock Issued | 53,682 | 53,682 | 15,989 | 14,427 | 2,579 |
| Other Financing Activity | 9,950 | 9,950 | 9,950 | 0 | 50 |
| Financing Cash Flow | $63,456 | $63,455 | $25,939 | $14,427 | $3,249 |
| Beginning Cash Position | 1,859 | 1,859 | 1,859 | 1,859 | 877 |
| End Cash Position | 27,605 | 38,884 | 13,386 | 13,271 | 1,859 |
| Net Cash Flow | $25,746 | $37,025 | $11,527 | $11,412 | $982 |
| Free Cash Flow | |||||
| Operating Cash Flow | -37,703 | -26,423 | -14,409 | -3,015 | -2,265 |
| Capital Expenditure | -7 | -7 | -3 | N/A | -2 |
| Free Cash Flow | -37,710 | -26,430 | -14,412 | -3,015 | -2,267 |